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Abstract
Enhancing cognitive performance with substances–especially prescription drugs–is a fiercely debated topic among scholars
and in the media. The empirical basis for these discussions is limited, given that the actual nature of factors that influence
the acceptability of and willingness to use cognitive enhancement substances remains unclear. In an online factorial survey,
contextual and substance-specific characteristics of substances that improve academic performance were varied
experimentally and presented to respondents. Students in four German universities rated their willingness to use and
moral acceptance of different substances for cognitive enhancement. We found that the overall willingness to use
performance enhancing substances is low. Most respondents considered the use of these substances as morally
unacceptable. Situational influences such as peer pressure, policies concerning substance use, relative performance level of
peers, but also characteristics of the substance, such as perceptions of substance safety, shape the willingness and
acceptability of using a substance to enhance academic performance. Among the findings is evidence of a contagion effect
meaning that the willingness was higher when the respondents have more CE drug users in their social network. We also
found deterrence effects from strong side effects of using the substance, as well as from policy regulations and sanctions.
Regulations might activate social norms against usage and sanctions can be seen as costly to users. Moreover, enhancement
substances seem to be most tempting to low performers to catch up with others compared to high performers. By
identifying contextual factors and substance characteristics influencing the willingness and acceptability of cognitive
enhancers, policy approaches could consider these insights to better manage the use of such substances.
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Introduction
Cognitive enhancement (CE) refers to a set of practices aiming
to augment cognitive capacities (e.g., memory, concentration) in
healthy individuals, usually with the goal of improving academic
or professional performance [1,2,3,4]. Much of the discussion
around cognitive enhancement is centered on the use of various
substances. These substances can be over-the-counter (OTC)
drugs (e.g., vitamin pills; guarana products); drugs that are only
available in pharmacies (e.g., caffeine tablets); prescription drugs
(e.g., donepezil, modafinil, methylphenidate), or illegal drugs (e.g.,
cocaine; ecstasy). In Germany, where the present study was
conducted, drug availabilities differ compared to the US, for
example. While OTC drugs can be also purchased outside of
pharmacies in Germany, drugs that are only available in
pharmacies can only be sold by professional personnel, without
requiring a prescription.
Prevalence studies on the use of pharmaceuticals for CE have
recently attracted attention from different stakeholders such as
medical societies, clinicians, and bioethicists [5,6]. These studies
have suggested that a proportion of students (1.3 to 11% in mostly
North American campuses) have reported using prescription
stimulants to augment their studying abilities and academic
performance [7,8,9,10,11]. The health risks involved in using
these medications without medical supervision or indication are
not well-characterized and have generated concerns among
ethicists and scientists [6,12,13]. There is some evidence of other
substances that are used for CE such as cocaine, ecstasy, or
amphetamine [9,10,14]. Caffeinated substances such caffeine
tablets or caffeinated drinks are well-known means of CE
[7,9,15]. Some authors describe caffeine and other OTC drugs
such as vitamin pills as ‘‘soft-enhancers’’ and found a prevalence of
5% among German students [10]. A combined measure of
pharmaceuticals, illicit drugs, and caffeine tablets revealed a
prevalence of 20% also among German students aiming to
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enhance cognitive performance [16]. A similar rate (16%) was
found in a small-scale study among Italian students without
reporting the type of substance used [17]. However, the authors
assume that a reasonable share refers to OTC drugs.
Perhaps of most concern are the effects of different factors
within academic environments such as the pressure to succeed in
competitive environments, coercion from peers to use stimulants as
enhancers, and the belief that medications represent efficacious
means of improving academic performance that may encourage
individuals to use such substances [1,9,11,18,19]. However, the
evidence needed to inform and address many of the scientific and
ethical concerns regarding CE is lacking. Several recent articles
have underscored inconclusive support for the efficacy of
medications used as cognitive enhancers
[1,6,12,20,21,22,23,24,25,26]. Other studies have highlighted a
persistent knowledge gap with respect to general prevalence of the
non-medical use of medications for enhancement [27,28]. Further,
there has been an unfortunate parallel between the prevalence of
substance use and actual desirability of cognitive enhancers in
academic and professional environments. This relationship has led
to the assumption of imminent public demand and acceptance,
requiring urgent ethical and policy responses [29,30]. Academic
ethicists have produced fiercely opposing responses on issues such
as fairness and on the types of mechanisms that are needed to
regulate enhancement substance use [12,31]. Still, the reactions of
students toward regulations concerning enhancement substance
use in universities e.g., in test-taking situations or for other
academic purposes remain to be elucidated. Furthermore, little is
generally known about the influence of contextual factors and
characteristics of substances on decision-making process of
individuals considering the non-medical use of prescription
medication for CE [12,26,32,33,34,35,36]. Thus, the search for
efficient policies cannot be based only on well-documented
mechanisms behind substance consumption.
Given the importance attributed to notions of demand and
prevalence in the literature in the debate surrounding CE, we
aimed to empirically examine the willingness to use CE substances
among students and the general acceptability of their usage. We
were also interested in assessing the factors which could influence
moral acceptability and willingness to engage in CE. Several
potential factors have been identified and were further investigated
in this study: a) impact of different types of substances; b) levels of
probability and severity of side effects [11,33,36,37]; c) current
performance level prior to substance use [11,34,38,39]; d)
perceived peer prevalence [2,10,18,36,40]; and e) influence of
policies regarding substance use [6]. We believe that additional
empirical data on these factors could assist ethicists, clinicians, and
scientists in navigating this debate and clarify their responsibility to




We employed a three-stage random selection procedure to
sample university students from four universities in different
academic disciplines. 2,127 students were invited to participate in
this self-administered web survey. In all, 1,852 students responded
(87.1%; completion rate 83.0%). 61.4% of the respondents were
female. Due to dropouts and item non-response, the analyses are
based on a reduced sample size (1,742 for willingness and 1,743 for
acceptability).
Partnering universities informed their students of the study via
post one week prior to the study in an effort to increase the
awareness of the subsequent email they would receive and to
motivate invitees to respond [41,42]. After one week, all students
received an email from their universities containing a personal link
to the survey, as well as up to two reminder mails. Students could
not fill out more than one survey. In order to achieve a higher
participation rate and higher data quality, participants of the study
received incentives with a value of EUR 5, e.g., [43]. We offered
five options at the end of the survey: money could be sent by mail,
sent to a PayPal account, replaced with a voucher for a popular
online retailer, or donated to UNICEF or Amnesty International.
Experimental Setting
We used a factorial survey–an experimental tool to investigate
causal effects in survey research–that consisted of descriptions, so
called vignettes [44,45,46,47,48,49], of substances that can
enhance academic performance. The vignettes provided informa-
tion on substance characteristics (type of substance, probability
and severity of side effects) and contextual factors (relative
performance, peer prevalence and policy). Each vignette consisted
of 6 dimensions with three or four levels (see Table 1). An example
of a vignette would read (text in square brackets indicates
experimentally varied information):
‘‘A university student, who has an important examination
soon, learns about the following substances that improve
academic performance: [a prescription drug]. In terms of
performance, the student is [among the worst 5% of students in
his age-group]. And substances like these are used by [half of his
fellow students]. The examination rules of his university [strictly
forbid the use of such substances to improve academic performance but
do not penalize students for doing so]. Furthermore, by taking the
substance [mild side effects are possible (e.g. slight restlessness or light
headache)]. These can occur in one of [10,000] users.’’
In total, our experimental setup contained 972 different
vignettes (combinations of factors). We applied a full factorial
design in which all vignettes were used and where a single vignette
was randomly assigned to each respondent. The vignette universe
also contained some extreme and rarely existing situations such as
the combination of OTC drugs with harmful side effects. This was
done to test how individuals would decide in theoretically
interesting, but rare, hypothetical, or future scenarios. We
introduced the hypothetical character of all vignettes by the
opening paragraph: ‘‘please imagine the following situation’’
signaling that students should put themselves in this situation and
imagine their reaction. None of the presented combinations were
logically impossible or unimaginable. Scholars have debated
whether extreme vignettes should be omitted in order to provide
respondents with more realistic scenarios or whether the vignettes
should be investigated and therefore allow scholars to learn from
these cases as well as to uphold the orthogonal design of their
experiment [50,51,52,53,54]. In this vignette study, we have opted
to preserve the extreme vignettes. Testing theoretically interesting,
hypothetical, or futuristic scenarios is one of the advantages of
vignette-based investigations. From the literature, we know that
OTC drugs can also be harmful. For example, drugs containing
ephedrine had some severe side effects such as severe heart valve
abnormalities [55,56,57]. Another report also provides evidence
for abuse and addiction from the use of OTC amphetamine-like
stimulants containing ephedrine, pseudoephedrine, and phenyl-
propanolamine [58]. Even energy drinks can be risky causing
unexpected deaths, as shown in warnings from the Food and Drug
Administration (FDA) [59]. To assess the impact of including
Perspectives on Cognitive Enhancement
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extreme cases in our results, we ran several additional analyses
(available upon request) to test the effect of excluding extreme
vignettes. No significant changes were found. This high stability of
the models and effect sizes can be understood as additional
indicators for the validity of the responses. Furthermore, we had
very low item non-response, which can be seen as an additional
indicator that responding to our vignettes was not problematic for
participants.
In the experimental setup each participant evaluated one
vignette. We chose vignettes for the given research question
because their hypothetical character reduces the tendency to
provide socially desirable answers compared to direct questioning
[60,61,62].
Dependent Variables
Willingness to Use a Substance. Participants were asked to
answer the question: ‘‘Please imagine the following situation: If
you were this student, would you take this substance?’’ We used a
10-point Likert-scale ranging from ‘‘under no circumstances’’ (0)
to ‘‘in every case’’ (9). Eight participants refused to answer the
question on willingness.
Moral acceptability. The moral perception of using a
substance as described was assessed with the question: ‘‘What is
your opinion about how morally acceptable it is to use this type of
substance to improve academic performance?’’ Responses were
gathered on a 10-point Likert-scale ranging from ‘‘totally
unacceptable’’ (0) to ‘‘completely acceptable’’ (9). Eight partici-
pants refused to provide their judgment about moral acceptability.
One half of the respondents received the question on moral
acceptability first; the other half received the question on the
willingness to use the substance first. We used this experimental
split to control for a question order effect. No influence of question
order was found for the willingness and the moral acceptability
measure.
Ethics Statement
In Germany, research studies in social science research are not
required to undergo formal ethics review. Formal ethics review is
only mandatory when the research objectives refer to issues which
are regulated on a legal basis (for instance in the German
Medicine Act (Arzneimittelgesetz, AMG), in the Medical Devices
Act (Medizinproduktegesetz, MGP), in the Stem Cell Research
Act (Stammzellenforschungsgesetz, StFG), or through the Medical
Association’s Professional Code of Conduct (Berufsordnung der
A¨rzte)). Given that none of the objectives of the present study fall
in the aforementioned categories, we were not obliged to seek
formal ethics approval. Our research design was guided by and
adheres to the ethical principles of the WMA Declaration of
Table 1. Vignette Dimensions and Levels used in this study.
Dimension Levels
1) Substance A university student, who has an important examination soon, learns about
the following substances that improve academic performance:
- an over-the-counter drug.
- a drug that is only available in pharmacies.
- a prescription drug.
- an illegal drug.
2) Severity of side effects Furthermore, by taking the substance…
- mild side effects are possible (e.g. slight restlessness or light headache).
- moderate side effects are possible (e.g. anxiety or nausea).
- severe side effects are possible (e.g. psychosis or heart attack).




4) Performance In terms of performance, the student is…
- among the worst 5% of students in his age-group.
- average for his age-group.
- among the best 5% of students in his age-group.
5) Peer prevalence And substances like these are used by…
- none of his fellow students.
- half of his fellow students.
- all of his fellow students.
6) Policy The examination rules of his university…
- do not forbid the use of such substances to improve academic performance.
- strictly forbid the use of such substances to improve academic performance but do not penalize students for doing so.
- strictly forbid the use of such substances to improve academic performance upon penalty of failing the exam.
Table 1 shows the varied dimensions of our vignettes and their levels. The order of dimensions in our study was: 1, 4, 5, 6, 2, and 3. To ease the presentation of results in
this article, we have changed the order and first present all substance properties (1, 2, 3), followed by all contextual factors (4, 5, 6).
doi:10.1371/journal.pone.0071452.t001
Perspectives on Cognitive Enhancement
PLOS ONE | www.plosone.org 3 August 2013 | Volume 8 | Issue 8 | e71452
Helsinki. The Data Protection Act of North Rhine Westphalia
(Datenschutzgesetz Nordrhein-Westfalen - DSG NRW, paragraph
28), stipulates that personal data should be anonymously
processed. Only in the case of coded or nominal data usage is
consent of participants is required. Our research design was
endorsed by the legal services of Bielefeld University. We
employed several measures to ensure the wellbeing and privacy
of study participants. We applied a fully anonymous survey design
in which we never accessed personal data of respondents such as
names, email or postal addresses we never accessed by us.
Partnering universities, which contacted the students, had no
access to survey data. Online responses were protected via secure
sockets layer protocols (SSL). The use of these mechanisms in
addition to our methods for data handling, data usage, and
deletion of data as well as the voluntariness of participation in this
research were communicated to all participants in disclosure
statements on the first page of the questionnaire and prior to
participation (i.e., pre-notification letter, a declaration of data
security, and emails). As we informed participants of conditions of
the study, we interpreted the act filling out the questionnaire as
implied consent. An official data protection officer supervised our
project and data collection. The data of this study are available
from the first author upon request.
Statistical Analysis
We applied multivariate negative binomial regression models
[63] to investigate how willingness and moral acceptability vary
with (1) different types of substances associated with a range of
probability and severity of side effects, and (2) within a context
where students are at different performance levels, having more
CE drug users in their social network, and subject to an absence/
presence of policies regarding substance use. This class of models is
appropriate for right-skewed distributions; it takes unobserved
heterogeneity among observations into account, and helps to get
more efficient, consistent and less biased estimates [64]. In our
analyses, we report effects as significant if they are below an a level
of 5%. Incidence rate ratios (IRR) above 1 indicate positive effects,
while those below 1 indicate negative effects and those equal 1
reveal no effect.
Results
Willingness to use a performance enhancing substance
According to our vignettes, the overall willingness to use
performance enhancing substances was low (see Figure 1). Almost
2 out of 3 (62.7%) participants stated that they would under no
circumstances decide to use a substance as described in the
vignette. Only a very small amount of students (1.5%) said they
would definitely use a substance for cognitive enhancement in
every case.
Applying a negative binomial regression model (see Model 1 in
Table 2), no significant differences in the decision outcome were
found when different types of substances were offered, be it an
OTC drug, a drug only available in pharmacies, a prescription
drug, or an illegal drug (see also Figure 2). Severe side effects (e.g.,
psychosis or heart attack) caused by the substance deterred the
willingness to enhance performance compared to mild (e.g., slight
restlessness or light headache; p,0.001) or moderate (e.g., anxiety
or nausea; p,0.001) side effects. An IRR of 0.638 indicates that
the mean willingness decreases by a factor of 0.683 or 31.7% ((1-
IRR)*100) comparing a situation of moderate with severe side
effects. Mild and moderate side effects (e.g., slight restlessness or
light headache) produced equal answers (p = 0.969). When side
effects occurred in one of 10,000 users, the willingness to take the
substance was higher than for a substance which provoked side
effects in one of 10 users (p = 0.005). The comparisons
concerning the probability of side-effects revealed no differences.
If the hypothetical student belonged to the 5% lowest performing
students in his class, the willingness to use the described substance
was significantly higher compared to a student with an average
performance (p,0.001) or to the top 5% performing students
(p,0.001). The willingness was also higher, when the hypothetical
student belonged to the average performance level instead of the
best (p = 0.045). The highest willingness was found when the
vignette scenario stated that every fellow student used the
substance. This willingness was significantly higher compared to
a situation when no fellow students (p,0.001) or half of the
students (p = 0.033) used the substance. In a situation where no
one used it, the willingness was also lower compared to one where
half of the students used it (p = 0.039). In a situation where the
examination rules of the university strictly forbade and penalized
the use of the substance, the willingness was lowest and equivalent
to a situation where it was forbidden but not penalized (p =
0.412). When there were no policies, students were much more
willing to use the substance compared to a policy with (p,0.001)
or without penalties (p = 0.001). In Model 2, we added control
variables and found that gender (p = 0.523) and age (p = 0.348)
had no impact on the evaluation of the vignettes. We used the
results from these models to gain insight on the most extreme
vignettes (those resulting in the empirically highest and the lowest
willingness). We combined the most attractive attributes of a
vignette concerning social context and characteristics of substances
(an OTC drug with mild side effects in 1 of 10,000 users in a
university with no policy, where one of the worst 5% is surrounded
by fellows who all take this substance). This analysis revealed a
relatively high predicted willingness to use the substance offered
(3.60), while it was very low for a more regulated substance and
less attractive context (0.35; an illegal substance with severe side
effects in 1 of 10 users in a university in which the substance is
forbidden and penalized and where one of the best 5% students is
surrounded by fellows who do not take this substance). This result
indicates that some combinations of substance characteristics and
contextual factors are seen as attractive and conducive to
responses in favor of using the drug.
Moral Acceptability of Using a Performance Enhancing
Substance
A substantial minority (42.5%) of participants considered
substance use, as described in the vignettes, as morally unaccept-
able and only a few (2.5%) found it completely acceptable (see
Figure 3).
Regression analyses showed that OTC drugs were seen as
morally more acceptable than prescription drugs (p = 0.007; see
Model 1 in Table 3; see also Figure 4) and illegal drugs (p =
0.033). No further differences were found between the types of
substance used for CE. Severe side effects reduced the acceptabil-
ity of substance use compared to mild (p = 0.010) or moderate
(p,0.001) side effects. Mild and moderate side effects produced
equal answers (p = 0.256). No association effect of the probability
of side effects was found. We also found no impact of the
performance level of the student on acceptability. Respondents
considered the use of the pill as (p = 0.025) morally more
acceptable when half of the fellows used it compared to a situation
when nobody used it. Further comparisons with regard to peer
prevalence showed no differences. Acceptability was higher when
the university did not forbid the use of the substance compared to
a situation when it was forbidden (p,0.001) or forbidden and
Perspectives on Cognitive Enhancement
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additionally punished (p,0.001). There was no difference between
forbidden use with or without a penalty (p = 0.546).
We found that men rated the type of substance as more
objectionable than women (p = 0.004, see Model 2), but we found
no effect of age (p = 0.493). For the moral acceptability, we also
investigated the most empirically extreme vignettes (as was done
for willingness with slight changes for the least attractive scenario:
prescription drugs instead of illegal drugs and average instead of
worst). When offering the most attractive attributes of a vignette
concerning social context and substance characteristics, the
acceptability was 3.37, while it was 1.11 for the least attractive
substance and context. Compared to similar analysis for willing-
ness, it can be concluded that willingness has a higher elasticity
with regard to situational stimuli than judgments about moral
acceptability.
Discussion
Summary and Interpretation of Results and Reflection on
Prior Research
A fierce debate has surfaced on the clinical and ethical
acceptance of CE. One indication of ethics acceptance could be
prevalence of use cognitive enhancing substances. However,
prevalence data has been criticized on methodological grounds
[65] and the actual nature of factors that encourage or discourage
CE substance use among the general public or students has not
been well characterized. Such information would be useful for
developing empirically-grounded regulations on substances used
for CE. This vignette-based study is among the first examining
influences on the willingness and judgment about moral accept-
ability of CE substance use. Most studies have concentrated only
on one or a few aspects of CE to study willingness and
acceptability. Our approach combined recurring issues in the
current debate on CE to present an exhaustive research design
that constructed specific social contexts and complex combinations
of characteristics of substances than previous studies. Our findings
are relevant to the discussion of rates of acceptability of and
willingness to engage in CE substance use, the factors affecting
them as well as implications for public health policies.
Low overall willingness and acceptability
We found overall very low willingness to engage in different
forms of CE as well as generally unfavorable attitudes toward the
moral acceptability of CE – especially when we provided less
attractive contexts and substance characteristics. These results
question previous statements found in highly cited commentaries
[6,12] and policy documents [66] stating the contrary. The
academic debate and media tempest surrounding CE have hinged
on the description of a widespread trend of misuse or non-medical
use of pharmaceuticals in students [5,8,27,28,29,34,38]. More-
over, public demand for CE has been predicted to be significant,
even to the point of making CE ‘‘inevitable’’ [18,19]. Guidance
from the American Academy of Neurology [66] and discussions
from other medical bodies has been triggered based partly on this
perception [5] and commentators have claimed the same [12,67].
Likewise, media coverage, internationally and in particular in the
US, has heralded a powerful trend of CE captured in enthusiastic
discourse [68,69]. Our findings therefore stand in contrast to prior
publications and comments suggesting widespread acceptance of
and willingness to engage in CE. Perhaps this contrast can be
partly explained by the German context of this study, which could
be less willing and accepting of CE, or a slow trend follower rather
than the trend setter in this area. Other potential reasons might be
differences in the legal and illegal access to enhancement
substances, restricted pharmaceutical advertisement in Germany
[9], pressure to succeed in universities, and culturally preferred
options for success (e.g., personal effort). In support of this
interpretation are recent prevalence data showing a lower trend of
CE on a large German campus [7,9,11]. However, CE studies
often focus on prescription drugs (in contrast to OTC drugs),
which might partially explain low prevalence rates. One study [16]
combining the assessment of different types of CE substances (illicit
drugs, prescription drugs, and caffeine tablets) already found a 12-
month prevalence of 20% among German university students.
Figure 1. MeanWillingness to Use a Substance for Enhancing Cognitive Performance.Measured on a 10-point Likert-scale with anchors: 0:
‘‘under no circumstances’’; 9: ‘‘in every case’’ (n = 1,742).
doi:10.1371/journal.pone.0071452.g001
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Moreover, Franke et al. [36] found a willingness to use
hypothetical enhancement substances which do not cause long-
term damages or addiction in 8 out of 10 high school and
undergraduate students but with a much lower reported preva-
lence of substances used for CE. Franke et al.’s results might
indicate that CE practices go beyond prescription drug use and
that CE could be a forthcoming trend, e.g., if more effective
substances were available, access on the Internet and black market
increases, or if the need for high and long lasting performance
continues. The relatively high proportion of 80% suggests that a
majority of students is tempted to use enhancers if they were safe.
In the absence of comparative data, this hypothesis merits further
consideration. However, at the very least, important caveats need
to be kept in mind in the international context of discussions about
CE. Indeed, if populations like the German students seem to be
recalcitrant to CE at the moment, the generalizability of the
American bioethics discussion could be compromised and further
attention to cultural aspects of the debate warranted. Even in
Canada and Australia, countries sharing many features with the
US (not including health care systems), critical opinions regarding
CE have been voiced by medical authorities [70,71] and scholars
[27,30,65]. Hence, it is an open question if assumptions of demand
have also been largely overestimated in the American context and
those of culturally proximate nations. Nonetheless, dissemination
of high estimates could be consequential. Focus group-based
research has found that stakeholders (university students, parents,
healthcare professionals) react strongly to media reporting on wide
prevalence and acceptance, and internalize this trend as being
inescapable and coercive CE [72].
Distinct factors shaping willingness and acceptability
Our study design allowed us to explore the effect of various
factors on willingness and acceptability. Our observations gener-
ally show that some factors discussed in the literature affect
willingness slightly more than they affect acceptability but,
contrary to what is sometimes implied, may not in themselves
have decisive consequences on willingness and moral acceptability.
Legal status of drug. We found that willingness was not
influenced by the legal status of the substance, but the acceptability
of OTC drugs was higher compared to prescription and illegal
drugs. One reason might be the differences in the access to these
substances and the fact that using and dealing prescription and
illegal drugs are forbidden.
Figure 2. Willingness to Use a Substance with Varying Characteristics and Under Differing Contextual Factors. In each panel: Mean
willingness to use a substance on a 10-point Likert-scale with anchors: 0: ‘‘under no circumstances’’; 9: ‘‘in every case’’ and corresponding error bars.
Panels A to C focus on the substance characteristics: (A) different types substances including an over-the-counter drug (OTC), pharmacy drug (PD),
prescription drug (PRD), and illegal drug (ID); (B) varying severity of side effects (mild, moderate, severe); and (C) differing probabilities that side
effects will occur (1 in 10.000, 1 in 100, 1 in 10). Panels D to F focus on varying contextual factors: (D) differing performance level relative to peers (low,
average, high); (E) prevalence of use among peers (0%, 50%, 100%); and (F) presence or absence of policy and sanction (no policy, policy without
sanctions, policy with sanction). (n = 1,742; refer to Table 1 for the full description of the vignette levels).
doi:10.1371/journal.pone.0071452.g002
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Side effects. In line with previous research [11,33,36,37], we
found a lower willingness for more severe and more probable side
effects. High severity, but not high probability of side effects,
decreased acceptability. Given the importance attributed to side
effects and potential health-risks [12,13], it can be argued that
individuals refrain from using substances having side effects
because, from a behavioral perspective, such effects can be
described as negative incentives or costs.
Normalizing and enhancement. Scholars have debated the
varying acceptability for users who want to normalize their
performance or those who want to enhance it [73]. However, we
did not find any effect of the current performance level on moral
acceptability. However, the willingness to use a substance was
much higher for low performers compared to others. When
considering the case of low performers, individuals might expect to
gain more when using a substance [11,34]. This might imply that
current discussions fail to capture that individuals instrumentally
react to the gains of using substances, but that in this case, moral
reasoning is not affected by rational deliberation on benefits. Prior
research also found a relationship between a low grade point
average or lower competencies and an increased non-medical use
of prescription medication [11,38,39].
Peer pressure. Our data show an increased willingness to
use a substance but higher acceptability when 50% of peers used
the substances compared to none. Also Franke et al. [36] found
that a share of students would be more willing to use enhancers if
Table 2. Negative binomial regression of willingness on vignette dimensions respondent’s sex and age.
Model 1 Model 2
IRR 95% CI IRR 95% CI
Substance
over-the-counter drug (OTC = Ref.)
pharmacy drug (PD) 0.874 [0.694–1.100] 0.872 [0.692–1.099]
prescription drug (PRD) 0.885 [0.701–1.117] 0.886 [0.702–1.117]
illegal drug (ID) 0.828 [0.662–1.035] 0.826 [0.660–1.033]
Severity of side effects
mild (Ref.)
moderate 1.004 [0.830–1.214] 0.999 [0.825–1.209]
severe 0.638*** [0.515–0.791] 0.638*** [0.515–0.790]
Probability of side effects
1/10,000 (Ref.)
1/100 0.857 [0.703–1.045] 0.862 [0.708–1.051]
1/10 0.746** [0.607–0.917] 0.747** [0.608–0.917]
Performance
low (Ref.)
average 0.692*** [0.569–0.841] 0.696*** [0.572–0.847]
high 0.555*** [0.452–0.682] 0.554*** [0.451–0.680]
Prevalence
0% (Ref.)
50% 1.248* [1.012–1.539] 1.243* [1.009–1.532]
100% 1.545*** [1.257–1.901] 1.538*** [1.251–1.891]
Policy
none (Ref.)
no sanction 0.712*** [0.587–0.862] 0.715*** [0.590–0.866]
sanction 0.650*** [0.529–0.798] 0.650*** [0.529–0.798]
Controls
male (Ref. = female) 1.058 [0.890–1.258]
age 0.976 [0.928–1.027]
Constant 2.469*** [1.853–3.291] 2.684*** [1.865–3.862]
Chi2 100.65*** 101.41***
Number of Vignette Evaluations 1,742 1,742
*p,0.05,
**p,0.01,
***p,0.001 (robust standard errors).
Table 2 shows the incidence rate ratios (IRR) and confidence intervals (CI) in parentheses of the willingness to use a CE substance on six vignette dimensions (Model 1)
and additionally adjusted for gender and age in Model 2.
doi:10.1371/journal.pone.0071452.t002
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others did. Generally, social networks are crucial factors in
decision-making in many spheres of life by providing influential
social information to individuals: they teach certain behaviors,
offer support or coercion about life goals, and influence norms to
be followed [18,74,75,76,77]. Consequently, a widespread use of
enhancement substances has been hypothesized to encourage their
use because: 1) substances might be perceived as beneficial and not
risky because many people use them; 2) not using them may lead
to feeling disadvantaged due to a relative lower performance [9],
therefore making substance use a strategic decision; and 3) it may
encourage the belief that it is not immoral to use them as CE is not
deviant behavior, so normalization about its use may occur
[40,77] and students may follow a ‘‘social heuristic’’ [74].
Policy. We found a lower willingness and a lower acceptabil-
ity when substance use was forbidden. Regulations not only
forbidding but sanctioning substance use did not present an
additional discouraging effect. The explanation of the effects found
is multifaceted and will be discussed in the next section.
Health policy implications for the use of substances for
CE
One important facet in discussions about enhancement
substances is regulation of their use [6]. To our knowledge, our
study is the first to provide results about the effect of regulations on
willingness and acceptability of CE substance use. Due to its
practical impact, we therefore wish to discuss this finding and its
meaning in greater detail. In the literature and in health policy, a
variety of positions can be classified following a spectrum of liberal
and conservative stances [78]. From a practical point of view, the
impact of these regulations is of high interest. Based on our results,
classifying substance use for enhancement purposes in universities
as cheating might activate social norms against usage, such as the
acknowledgement of the infringement of fairness. Social norms are
very influential on behavior [79,80,81] and our results consistently
support that regulations might restrict usage. Separate from our
study but connected to our data is the need to develop clearer
health policies about cognitive enhancement as a potential public
health concern.
CE has been described as a public health concern [82] but
claims to that effect have been criticized, based on rather low
prevalence rates [27]. However, given the important public
debate, academic discussions, and suspected higher prevalence
rates on some specific American campuses, some public health
authorities should consider acting to curtail CE. Our results
indicate that informing potential users about the prevalence of
severe side- effects could discourage the use of substances for CE.
Informing them about these health risks (e.g., via drug education
courses or the media) can be a promising means of prevention
[9,11,33,83]. Also, by simply having and promoting a policy
regarding CE, academic institutions could assume a firmer and
potentially more effective role in prevention strategies. This stance
reflects the opinion voiced in an editorial of the Canadian Medical
Association Journal, calling for stimulant abuse to be ‘‘recognized by
universities as a life-threatening issue and then denormalized’’
[71]. The finding that lower performance increases willingness can
be utilized by strengthening learning strategies for students who
may be straggling behind. Student-focused teaching methods
might also be an approach to improve a student’s self-perceived
competencies, but also to provide a more effective learning
environment [84,85]. We did not investigate the power of
traditional strategies to improve academic performance (e.g.,
tutoring, counseling) which could also have a powerful impact on
practices. The efficacy of these strategies compared to those of
substances we studied would be worthy of investigation before
policy action is taken. We did not examine the impact of broader
actions (e.g., legislative) and sanctions beyond the academic
context, which could also extend the effect seen in university
policies. These other options merit further attention from ethicists
and policy-makers and call for further research. However, our
data suggest that different substances used for enhancement could
be targeted collectively given similar willingness towards and
acceptability of types of substances used for the specific goal of
enhancement.
Figure 3. Mean Moral Acceptability about Using a Substance for Enhancing Cognitive Performance. Measured on a 10-point Likert-scale
with anchors: 0: ‘‘totally unacceptable’’; 9: ‘‘completely acceptable’’ (n = 1,743).
doi:10.1371/journal.pone.0071452.g003
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Limitations of the Study
There are a few limitations to the results of our study. 1) Not all
invited participants filled out the questionnaire. However, our
response rate (87.1%) did reach the upper end of the rate achieved
in previous studies (22 to 86%) [38]. In addition, the number of
item non-response remained very low. However, the impact of
nonresponse might be negligible regarding the interpretation of
the results because we conducted an experiment where every
student was randomly assigned to a vignette. So, all contextual
factors and characteristics of substances are uncorrelated with
characteristics of respondents. Finally, our results were controlled
for effects of age and gender. 2) The questions regarding substance
use are sensitive. Especially for non-anonymous surveys, this
results in a risk of downward-biased prevalence rates [86,87].
However, online-surveys provide a high level of anonymity and as
stated in the methods section, we employed multiple measures to
protect answers of respondents and to ensure high data quality
(e.g., full anonymity of the survey and supervision of an official
data protection officer). Furthermore, it is known that the
hypothetical character of factorial survey designs is more immune
to skewing answers towards social desirability than direct
questioning [60,61,62]. Moreover, the low item non-response rate
for these questions can be indicative of a low perceived sensitivity
of the question and a high perceived confidentiality of answers. We
also tested whether the respondents’ perceived anonymity of this
survey had an impact on the willingness and the acceptability
measure but found no effects (results are available upon request). 3)
We surveyed students only. The general population might react
differently to our vignettes due to different needs and preferences.
However, students are a population at risk of using enhancers
because of pressures to succeed and the valuing of cognitive
performance. Therefore, they might belong to a group of ‘‘early
adopters’’ [12]. Nevertheless, replicating our study with the
general population might reveal interesting insights. 4) We
analyzed the willingness and acceptability in one country. As
discussed above, results in different countries might differ.
Though, multi-country studies would be helpful to get more
insights and to compare the impact of contextual factors and
substance characteristics. 5) Due to a lack of statistical power, we
were not able to experimentally vary and investigate all potential
influences in our study. It would be important to know more about
the impact of other factors (such as the price of getting relevant
substances, access, or effectiveness). However, we used an
Figure 4. Moral Acceptability of Using a Substance with Varying Characteristics and Differing Contextual Factors. In each panel: Mean
moral acceptability about the use of a substance on a 10-point Likert-scale with anchors: 0: ‘‘totally unacceptable’’; 9: ‘‘completely acceptable’’ and
corresponding error bars. Panels A to C focus on the substance characteristics: (A) different types substances including an over-the-counter drug
(OTC), pharmacy drug (PD), prescription drug (PRD), and illegal drug (ID); (B) varying severity of side effects (mild, moderate, severe); and (C) differing
probabilities that side effects will occur (1 in 10.000, 1 in 100, 1 in 10). Panels D to F focus on varying contextual factors: (D) differing performance
level relative to peers (low, average, high); (E) prevalence of use among peers (0%, 50%, 100%); and (F) presence or absence of policy and sanction (no
policy, policy without sanctions, policy with sanction). (n = 1,743; refer to Table 1 for the full description of the vignette levels).
doi:10.1371/journal.pone.0071452.g004
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experimental approach, so the impact of potential confounders
was reduced.
Conclusion
Using an online factorial survey design with vignettes, we
investigated the moral acceptability of and willingness to use
enhancement substances. In spite of claims to the contrary in the
literature, we found limited willingness to engage in, and moral
acceptability of enhancement using substances like prescription
and illicit drugs. Several factors (types of substances, probability
and severity of side effects, different performance levels, number of
CE drug users in the social network, and policies regarding
substance use) influenced willingness and moral acceptability.
Future research should address similar questions in an interna-
tional context and extend the scope of influential dimensions, such
as access to substances. Public interventions should take into
consideration both the lack of general acceptance found in this
study as well as factors that would deter use, such as highlighting
the health risks of substance use, which could support effective
health education or public health policies.
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